We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Read MoreHide Full Article
Key Takeaways
ESPR reported Q4 EPS of 22 cents, missing estimates, while revenues jumped 144% to $168.4M and beat forecasts.
ESPR's collaboration revenues surged 232% to $124.7M, driven by a one-time $90M payment from Otsuka.
ESPR agreed to acquire Corstasis, adding Enbumyst nasal spray to expand its cardiovascular franchise.
Esperion Therapeutics (ESPR - Free Report) reported earnings per share (EPS) of 22 cents for the fourth quarter of 2025, missing the Zacks Consensus Estimate of 23 cents. The company had incurred a loss of 10 cents per share (excluding loss on extinguishment of debt) in the year-ago quarter.
Esperion generated total revenues of $168.4 million in the fourth quarter, representing a 144% year-over-year increase. Total revenues beat the Zacks Consensus Estimate of $161 million.
Shares of Esperion were down around 11% on March 10, probably due to the mixed results, indicating that the earnings miss might have hurt investors' sentiments.
Over the past year, the stock has surged 77.6% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol (bempedoic acid) and Nexlizet, which are approved for the treatment of elevated LDL-C (bad cholesterol) and for cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe.
The oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
ESPR's Q4 Results in Detail
Product revenues, solely from the United States, totaled $43.7 million in the fourth quarter, up 38% year over year. Product revenues missed our model estimate of $79 million.
Esperion recorded collaboration revenues, including combined royalty and partner revenues, of $124.7 million in the fourth quarter, up 232% year over year. This was driven by a one-time $90 million payment from Otsuka following regulatory approval, a favorable National Health Insurance price listing and higher royalty sales in partner territories and product sales to collaboration partners under supply agreements.
Collaboration revenues beat the Zacks Consensus Estimate and our model estimate of $92 million and $88.3 million, respectively.
Research and development expenses increased 26% from the year-ago period to $13.9 million, reflecting higher costs in ongoing clinical studies.
Selling, general and administrative expenses were up 12% year over year to $41.4 million owing to higher legal costs associated with the abbreviated new drug application (“ANDA”) litigation.
As of Dec. 31, 2025, Esperion had cash, cash equivalents, restricted cash and investment securities of $167.9 million compared with $92.4 million as of Sept. 30, 2025.
ESPR’s Full-Year 2025 Results
For 2025, Esperion reported total revenues of $403.1 million, which rose 21% year over year.
For full-year 2025, the company recorded a net loss of 11 cents per share.
ESPR’s 2026 Guidance
Esperion expects operating expenses to range from $225 million to $255 million, including $15 million in non-cash expenses related to stock compensation for 2026.
ESPR's Key Recent Developments
Esperion entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, earlier this month. The transaction is expected to be closed in the second quarter of 2026, subject to fulfillment of customary closing conditions.
The impending acquisition will add Corstasis’ lead product, Enbumyst (bumetanide nasal spray), to Esperion’s commercial portfolio, which is expected to strengthen and expand the company’s cardiovascular franchise.
Enbumyst is the first and only nasal spray diuretic approved by the FDA for the treatment of edema with congestive heart failure (CHF) and hepatic and renal disease in adults.
Per management, the addition of Enbumyst through the acquisition of Corstasis is likely to help Esperion target a potential market opportunity of more than $4 billion in the United States.
In February, Esperion reached a settlement agreement with Alkem Laboratories Ltd. following an earlier agreement with Dr. Reddy’s (RDY - Free Report) , related to patents for Nexletol and Nexlizet. The settlement agreement resolves the patent litigation brought by Esperion against Alkem and RDY’s ANDA, seeking marketing approval for a generic version of each of Nexletol and Nexlizet in the United States before the applicable patents expire.
Per the settlement terms, Alkem Laboratories and Dr. Reddy’s have agreed not to launch a generic version of Nexletol or Nexlizet in the United States before April 19, 2040, except under certain limited conditions that are customarily included in such agreements.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 16.9% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $9.00 for 2026. Over the past year, shares of ANIP have surged 20%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Key Takeaways
Esperion Therapeutics (ESPR - Free Report) reported earnings per share (EPS) of 22 cents for the fourth quarter of 2025, missing the Zacks Consensus Estimate of 23 cents. The company had incurred a loss of 10 cents per share (excluding loss on extinguishment of debt) in the year-ago quarter.
Esperion generated total revenues of $168.4 million in the fourth quarter, representing a 144% year-over-year increase. Total revenues beat the Zacks Consensus Estimate of $161 million.
Shares of Esperion were down around 11% on March 10, probably due to the mixed results, indicating that the earnings miss might have hurt investors' sentiments.
Over the past year, the stock has surged 77.6% compared with the industry’s 2.2% growth.
Image Source: Zacks Investment Research
Esperion has two FDA-approved drugs in its commercial portfolio, Nexletol (bempedoic acid) and Nexlizet, which are approved for the treatment of elevated LDL-C (bad cholesterol) and for cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe.
The oral drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets (excluding Japan, where the company has a collaboration with Otsuka Pharmaceuticals) in partnership with Daiichi Sankyo. The company records royalties on sales of its drugs in ex-U.S. markets.
ESPR's Q4 Results in Detail
Product revenues, solely from the United States, totaled $43.7 million in the fourth quarter, up 38% year over year. Product revenues missed our model estimate of $79 million.
Esperion recorded collaboration revenues, including combined royalty and partner revenues, of $124.7 million in the fourth quarter, up 232% year over year. This was driven by a one-time $90 million payment from Otsuka following regulatory approval, a favorable National Health Insurance price listing and higher royalty sales in partner territories and product sales to collaboration partners under supply agreements.
Collaboration revenues beat the Zacks Consensus Estimate and our model estimate of $92 million and $88.3 million, respectively.
Research and development expenses increased 26% from the year-ago period to $13.9 million, reflecting higher costs in ongoing clinical studies.
Selling, general and administrative expenses were up 12% year over year to $41.4 million owing to higher legal costs associated with the abbreviated new drug application (“ANDA”) litigation.
As of Dec. 31, 2025, Esperion had cash, cash equivalents, restricted cash and investment securities of $167.9 million compared with $92.4 million as of Sept. 30, 2025.
ESPR’s Full-Year 2025 Results
For 2025, Esperion reported total revenues of $403.1 million, which rose 21% year over year.
For full-year 2025, the company recorded a net loss of 11 cents per share.
ESPR’s 2026 Guidance
Esperion expects operating expenses to range from $225 million to $255 million, including $15 million in non-cash expenses related to stock compensation for 2026.
ESPR's Key Recent Developments
Esperion entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, earlier this month. The transaction is expected to be closed in the second quarter of 2026, subject to fulfillment of customary closing conditions.
The impending acquisition will add Corstasis’ lead product, Enbumyst (bumetanide nasal spray), to Esperion’s commercial portfolio, which is expected to strengthen and expand the company’s cardiovascular franchise.
Enbumyst is the first and only nasal spray diuretic approved by the FDA for the treatment of edema with congestive heart failure (CHF) and hepatic and renal disease in adults.
Per management, the addition of Enbumyst through the acquisition of Corstasis is likely to help Esperion target a potential market opportunity of more than $4 billion in the United States.
In February, Esperion reached a settlement agreement with Alkem Laboratories Ltd. following an earlier agreement with Dr. Reddy’s (RDY - Free Report) , related to patents for Nexletol and Nexlizet. The settlement agreement resolves the patent litigation brought by Esperion against Alkem and RDY’s ANDA, seeking marketing approval for a generic version of each of Nexletol and Nexlizet in the United States before the applicable patents expire.
Per the settlement terms, Alkem Laboratories and Dr. Reddy’s have agreed not to launch a generic version of Nexletol or Nexlizet in the United States before April 19, 2040, except under certain limited conditions that are customarily included in such agreements.
Esperion Therapeutics, Inc. Price, Consensus and EPS Surprise
Esperion Therapeutics, Inc. price-consensus-eps-surprise-chart | Esperion Therapeutics, Inc. Quote
ESPR’s Zacks Rank & Stocks to Consider
Esperion currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.82. CPRX shares have gained 16.9% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.28 to $9.00 for 2026. Over the past year, shares of ANIP have surged 20%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.